SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.

Saved in:
Bibliographic Details
Title: SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.
Authors: Alkayyal AA; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Ajina R; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Cacciabue M; Instituto de Agrobiotecnología y Biología Molecular (IABIMO), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), De los Reseros y N. Repetto s/n, Hurlingham, Buenos Aires, Argentina.; Departamento de Ciencias Básicas, Universidad Nacional de Luján, Luján, Buenos Aires, Argentina., Alkayyal AA; College of Medicine, Taibah University, Almadinah Almunwarah, Saudi Arabia., Saeedi NH; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia., Hussain Alshehry T; King Abdullah International Medical Research Centre, King Saud University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Kaboha F; King Abdullah International Medical Research Centre, King Saud University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Alotaibi MA; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.; King Abdullah International Medical Research Centre, King Saud University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Zaidan N; King Abdulaziz City for Science and Technology-Brigham and Women's Hospital (KACST-BWH) Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia., Shah K; Center for Stem Cell and Translational Immunotherapy (CSTI), Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, United States., Alroqi F; Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Immunology, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.; Faculty of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Bakur Mahmoud A; College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.; Strategic Research and Innovation Laboratories, Taibah University, Madinah, Saudi Arabia.; Immunology Research Program, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Source: Frontiers in immunology [Front Immunol] 2023 Jan 31; Vol. 14, pp. 1082191. Date of Electronic Publication: 2023 Jan 31 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1082191